R-059. Extremely severe ovarian hyperstimulation syndrome despite withholding gonadotrophin during ovarian stimulation for IVF

Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?

Withholding gonadotrophin administration (coasting) may prevent severe ovarian hyperstimulation syndrome (OHSS). To ascertain the effectiveness of this protection a cohort of 252 consecutive in-vitro fertilization (IVF) or IVF with intracytoplasmic sperm injection (ICSI) cycles was studied. Twenty women with exaggerated response were treated with coasting. Despite coasting, four patients develo...

Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.

BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic and potentially life threatening condition resulting from excessive ovarian stimulation. Reported incidence varies from 1% to 10% of in vitro fertilization (IVF) cycles. The factors contributing to OHSS have not been completely explained. The release of vasoactive substances secreted by the ovaries under human chorionic gonado...

Nephrotic Sydrome Developing in Severe Ovarian Hyperstimulation Syndrome

[Severe ovarian hyperstimulation syndrome: a case report].

puntuación entre 0 y 3. Es también interesante observar que el mayor porcentaje de nuestros pacientes (64,2%) presentaba valores por encima de 7 y dentro del grupo de 4–7, todos obtuvieron una puntuación de 6-7, lo que indicarı́a en parte la necesidad de analizar los puntos de corte tal y como señala el autor. Por ejemplo, un paciente con puntuación de 6 que se enfrenta a un trayecto de cerca de...

High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.

This case report describes the first attempt to treat imminent ovarian hyperstimulation syndrome (OHSS) by using a gonadotrophin-releasing hormone (GnRH) antagonist. A 33 year old, normo-ovulatory woman undergoing in-vitro fertilization received daily subcutaneous injections of 150 IU of recombinant follicle-stimulating hormone (recFSH) from cycle day 2, together with GnRH antagonist (ganirelix...